TYMS and neoplasm: At least four studies have suggested that patients whose primary tumours had high TS expression may benefit from FU-based adjuvant treatment, while those whose tumours had low expression do not (Johnston et al, 1994; Yamachika et al, 1998; Takenoue et al, 2000; Edler et al, 2002).